InvivoGen provides an expanding collection of Raji cells that stably express immune checkpoints (ICs).
These human B lymphocyte-derived cells were originally isolated from a Burkitt’s lymphoma patient and are characterized by a number of surface-expressed markers including the B cell receptor (BCR), CD19, and CD20. Additionally, they naturally express various levels of ICs such as CD27, CD70, CD80, PD-L1, and 4-1BBL.
These cells can be used as target cells for a number of applications including CAR-T cell toxicity assays as well as human mAb effector studies, such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) assays, using InvivoGen's Jurkat-Lucia™ NFAT-CD16 cells or Jurkat-Lucia™ NFAT-CD32 cells, respectively.
InvivoGen's Raji cell collection is an integral part of our in-house quality control for our anti-human biosimilar IC mAbs.
